Joshua Yang
Director Ejecutivo en Glyphic Biotechnologies Inc .
Perfil
Joshua Yang is the founder of Nephrosant, Inc. (founded in 2017) and Glyphic Biotechnologies Inc (founded in 2021), where he holds the title of Chief Executive Officer.
He is currently an Advisor at Cantos Ventures, LLC.
Dr. Yang's education history includes a graduate degree and an MBA from Stanford University, an undergraduate degree from the University of California San Diego, graduate studies at the University of California, a doctorate from The Johns Hopkins University School of Medicine, and a doctorate from Johns Hopkins Berman Institute of Bioethics.
Cargos activos de Joshua Yang
| Empresas | Cargo | Inicio |
|---|---|---|
Glyphic Biotechnologies Inc
 Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | Director Ejecutivo | 01/01/2021 |
Cantos Ventures, LLC
 Cantos Ventures, LLC Investment ManagersFinance Cantos Ventures LLC (Cantos Ventures) is a venture capital firm founded in 2016 by Ian Rountree. The firm is headquartered in San Francisco, California. | Consultor / Asesor | - |
Nephrosant, Inc.
 Nephrosant, Inc. BiotechnologyHealth Technology Nephrosant, Inc. is a company dedicated to improving kidney health through noninvasive diagnostic tests. The company is based in Brisbane, CA. The company's flagship diagnostic test is QSant, a noninvasive urine-based test that supports early detection of kidney rejection risk. Nephrosant plans to develop centralized lab tests and point of care tests for kidney diseases and allograft monitoring for other organs. Founded in 2017 by Dr. Minnie Sarwal and UCSF physicians, the company has a team of world-class scientists, engineers, and clinicians who have licensed the founding team's clinical research to develop diagnostic tests for chronic kidney disease. Dr. Sarwal has been the CEO since 2017. | Fundador | 01/01/2017 |
Formación de Joshua Yang.
| Stanford University | Graduate Degree |
| Johns Hopkins Berman Institute of Bioethics | Doctorate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
| University of California | Graduate Degree |
| University of California San Diego | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Glyphic Biotechnologies Inc
Glyphic Biotechnologies Inc Miscellaneous Commercial ServicesCommercial Services Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation. | Commercial Services |
Cantos Ventures, LLC
Cantos Ventures, LLC Investment ManagersFinance Cantos Ventures LLC (Cantos Ventures) is a venture capital firm founded in 2016 by Ian Rountree. The firm is headquartered in San Francisco, California. | Finance |
Nephrosant, Inc.
Nephrosant, Inc. BiotechnologyHealth Technology Nephrosant, Inc. is a company dedicated to improving kidney health through noninvasive diagnostic tests. The company is based in Brisbane, CA. The company's flagship diagnostic test is QSant, a noninvasive urine-based test that supports early detection of kidney rejection risk. Nephrosant plans to develop centralized lab tests and point of care tests for kidney diseases and allograft monitoring for other organs. Founded in 2017 by Dr. Minnie Sarwal and UCSF physicians, the company has a team of world-class scientists, engineers, and clinicians who have licensed the founding team's clinical research to develop diagnostic tests for chronic kidney disease. Dr. Sarwal has been the CEO since 2017. | Health Technology |
- Bolsa de valores
- Insiders
- Joshua Yang
